摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trans 3-(3,5-dichlorophenyl)-2-propenoic acid chloride | 695187-26-9

中文名称
——
中文别名
——
英文名称
trans 3-(3,5-dichlorophenyl)-2-propenoic acid chloride
英文别名
(E)-3-(3,5-dichlorophenyl)prop-2-enoyl chloride
trans 3-(3,5-dichlorophenyl)-2-propenoic acid chloride化学式
CAS
695187-26-9
化学式
C9H5Cl3O
mdl
——
分子量
235.497
InChiKey
MWXYXKHYLGUUQF-OWOJBTEDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    338.6±37.0 °C(Predicted)
  • 密度:
    1.446±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists
    摘要:
    A series of phenyl piperidine derivatives possessing potent and selective CCR2 antagonist activity is reported. Structure activity relationship (SAR) studies have established that incorporation of a second ring system adjacent to the aryl piperidine plays an important role in determining the CCR2 potency. Both a second piperidine ring and a 1,3-substituted cyclopentylamine have been probed as linkers. For the cyclopentylamine series, the IS,3R-configuration exhibits much higher affinity for hCCR2 than the 1R,3S-configuration. Compound 3g shows good selectivity over CCR 1, CCR3, 5-HT and has an excellent P450 profile. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.07.065
  • 作为产物:
    描述:
    (2E)-3-(3,5-二氯苯基)丙烯酸 在 草酰氯 作用下, 以 二氯甲烷 为溶剂, 生成 trans 3-(3,5-dichlorophenyl)-2-propenoic acid chloride
    参考文献:
    名称:
    Design, Synthesis and Cytotoxic Evaluation of Novel Imatinib Amide Derivatives that Target Abl Kinase
    摘要:
    新型的伊马替尼酰胺衍生物(a1-28, b1-9)被合成并评估了它们的生物活性。所有化合物均通过1H NMR、质谱及元素分析进行了表征。在所有衍生物中,化合物a4、a10、a21、b1和b2显示出最强的抑制K562细胞增殖能力,其IC50值分别为0.67、0.66、0.65、0.59和0.62 µM,表明这些化合物是白血病K562细胞中Bcr-Abl的有效抑制剂,与参考化合物伊马替尼相当。分子对接研究用于将化合物a21和b1定位到Abl的活性位点,以确定可能的结合模式。
    DOI:
    10.2174/1570180811666140812231519
点击查看最新优质反应信息

文献信息

  • Development of sulfonamides incorporating phenylacrylamido functionalities as carbonic anhydrase isoforms I, II, IX and XII inhibitors
    作者:Srinivas Angapelly、P.V. Sri Ramya、Andrea Angeli、Sonia Del Prete、Clemente Capasso、Mohammed Arifuddin、Claudiu T. Supuran
    DOI:10.1016/j.bmc.2017.08.047
    日期:2017.10
    sub-nanomolar inhibition constants against hCA II (KIs in the range of 0.50–50.5 nM), hCA IX (KIs of 1.8–228.5 nM), and hCA XII (KIs of 3.5–96.2 nM) being less effective as inhibitors of the off target isoform hCA I. A detailed structure–activity relationship study demonstrates that the nature and position of substituents present on the aromatic part of the scaffold strongly influence the inhibition of CA
    合成了一系列结合了苯基丙烯酰胺基官能团的新型磺酰胺,并研究了其对金属酶碳酸酐酶的抑制作用(CA,EC 4.2.1.1)。生理和药理学相关的人类(h)亚型hCA I和II(胞质同工酶),以及与跨膜肿瘤相关的hCA IX和XII也包括在研究中。这些化合物对hCA II(K I s在0.50-50.5 nM范围内),hCA IX(K I s在1.8-228.5 nM范围内)和hCA XII(K I3.5-96.2 nM s)作为脱靶同工型hCA I抑制剂的效果较差。详细的结构-活性关系研究表明,在支架的芳香部分存在的取代基的性质和位置强烈影响对CA同工型的抑制。由于hCA II,IX和XII参与了诸如青光眼和低氧以及转移性肿瘤等病理过程,因此这项工作中报道的这类化合物可能是有用的临床前候选药物。
  • Novel non-peptidic neuropeptide Y Y 2 receptor antagonists
    作者:Jill A. Jablonowski、Wenying Chai、Xiaobing Li、Dale A. Rudolph、William V. Murray、Mark A. Youngman、Scott L. Dax、Diane Nepomuceno、Pascal Bonaventure、Timothy W. Lovenberg、Nicholas I. Carruthers
    DOI:10.1016/j.bmcl.2003.12.057
    日期:2004.3
    Through SAR studies of a piperidinylindoline cinnamide HTS lead, the first potent, non-peptide, low molecular weight selective Neuropeptide Y Y-2 (NPY Y-2) antagonists have been synthesized. The SAR studies around the piperidinyl, the indolinyl, and the cinnamyl moieties are discussed. (C) 2003 Elsevier Ltd. All rights reserved.
  • [EN] BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE ACID DERIVATIVES AND THEIR USE AS HEPARANASE INHIBITORS<br/>[FR] DERIVES D'ACIDES DE BENZOXAZOLE, DE BENZOTHIAZOLE, ET DE BENZIMIDAZOLE PHARMACEUTIQUEMENT ACTIFS
    申请人:OXFORD GLYCOSCIENCES UK LTD
    公开号:WO2004046122A2
    公开(公告)日:2004-06-03
    Compounds of formula (I): wherein R1, R2 and R3 are independently, hydrogen, halogen, CF3, OR6, NR7R8, NR8COR10, NR8SO2R10 or C1-6 alkyl optionally substituted by hydroxy, C1-6 alkoxy or NR7R8; R4 is NR8CONR8R9, NR8COR9, NR8SO2R9, or W-CONR8R9, where W is a bond, C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene; and R5 is Formula (A) methods for their synthesis, pharmaceutical compositions comprising them and their use in medicine, in particular for the treatment of cancer.
  • Design, Synthesis and Cytotoxic Evaluation of Novel Imatinib Amide Derivatives that Target Abl Kinase
    作者:Ri-Sheng Yao、Qiu-Xiang Guan、Xiao-Qin Lu、Ban-Feng Ruan
    DOI:10.2174/1570180811666140812231519
    日期:2014.10.30
    Novel imatinib amide derivatives (a1-28, b1-9) were synthesized and evaluated for their biological activities. All compounds were characterized by 1H NMR, MS and elemental analysis. Among all the derivatives, compounds a4, a10, a21, b1 and b2 displayed the most significant ability of inhibiting K562 cell proliferation with the IC50 values of 0.67, 0.66, 0.65, 0.59 and 0.62 µM, respectively, indicating that these compounds were potent inhibitors of Bcr-Abl in leukemic K562 cells, comparable to the reference compound imatinib. Molecular docking study was performed to position compounds a21 and b1 into the active site of Abl to determine the probable binding modes.
    新型的伊马替尼酰胺衍生物(a1-28, b1-9)被合成并评估了它们的生物活性。所有化合物均通过1H NMR、质谱及元素分析进行了表征。在所有衍生物中,化合物a4、a10、a21、b1和b2显示出最强的抑制K562细胞增殖能力,其IC50值分别为0.67、0.66、0.65、0.59和0.62 µM,表明这些化合物是白血病K562细胞中Bcr-Abl的有效抑制剂,与参考化合物伊马替尼相当。分子对接研究用于将化合物a21和b1定位到Abl的活性位点,以确定可能的结合模式。
  • Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists
    作者:Mingde Xia、Cuifen Hou、Scott Pollack、James Brackley、Duane DeMong、Meng Pan、Monica Singer、Michele Matheis、Gil Olini、Druie Cavender、Michael Wachter
    DOI:10.1016/j.bmcl.2007.07.065
    日期:2007.11
    A series of phenyl piperidine derivatives possessing potent and selective CCR2 antagonist activity is reported. Structure activity relationship (SAR) studies have established that incorporation of a second ring system adjacent to the aryl piperidine plays an important role in determining the CCR2 potency. Both a second piperidine ring and a 1,3-substituted cyclopentylamine have been probed as linkers. For the cyclopentylamine series, the IS,3R-configuration exhibits much higher affinity for hCCR2 than the 1R,3S-configuration. Compound 3g shows good selectivity over CCR 1, CCR3, 5-HT and has an excellent P450 profile. (c) 2007 Elsevier Ltd. All rights reserved.
查看更多